Tonix Pharmaceuticals shares rise 1.47% premarket after announcing new data on Mpox and Smallpox vaccine candidate TNX-801.

martes, 12 de agosto de 2025, 7:16 am ET1 min de lectura
TNXP--
Tonix Pharmaceuticals Holding Corp. rose 1.47% in premarket trading, with the company announcing the presentation of new data on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025. Additionally, the company published Phase 3 RESILIENT Trial results of TNX-102 SL for Fibromyalgia in the peer-reviewed journal Pain Medicine, and positive preclinical data of mTNX-1700 in gastric cancer animal models in the Cancer Cell journal.

Tonix Pharmaceuticals shares rise 1.47% premarket after announcing new data on Mpox and Smallpox vaccine candidate TNX-801.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios